Key opinion Leader if the field of cancer immunology with over 100 peer-reviewed publications, I have identified the adenosine-producing enzyme CD73 as a novel cancer target (Stagg, PNAS, 2010) and I participated in the development of several adenosine-targeting agents now in clinical trials. My work was also the first to demonstrate that trastuzumab (Herceptin) mediates its activity via adaptive T cell responses and synergizes with anti-PD-1 therapy (Stagg, PNAS, 2011). This led to approval of pembrolizumab (anti-PD-1) in combination with trastuzumab and chemotherapy for first-line treatment of advanced HER2-positive gastric or gastroesophageal adenocarcinoma. My lab is now focused at developing 'next-generation' of cancer immunotherapeutics.